Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVB-S6-500 + pegylated liposomal doxorubicin
- Development stage
- Phase 1
- Lead developer
- Aravive
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AVB-S6-500 + pegylated liposomal doxorubicin is a combination therapy under investigation for the treatment of platinum-resistant recurrent ovarian cancer. AVB-S6-500 (batiraxcept) is a recombinant fusion protein that specifically binds to the ligand growth arrest-specific 6 (GAS6), acting as an AXL inhibitor. By sequestering GAS6, AVB-S6-500 prevents activation of the AXL receptor tyrosine kinase, which is implicated in tumor growth, metastasis, and resistance to therapy. Pegylated liposomal doxorubicin is a formulation of doxorubicin encapsulated within liposomes coated with polyethylene glycol (PEG), which enhances circulation time and preferential delivery to tumors via the enhanced permeability and retention effect, reducing systemic toxicity. The combination is intended to target cancer growth and progression through both cytotoxic action (by doxorubicin) and inhibition of tumor cell survival signaling (by AXL inhibition)[1][5][2][7].
- Brand names
- Caelyx
- Other names
- PLD
02
Targets
AXL (AXL receptor tyrosine kinase)DNAGAS6 (Growth arrest-specific protein 6)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on AVB-S6-500 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVB-S6-500 + pegylated liposomal doxorubicin.